𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacodynamics of heparin in vascular surgery

✍ Scribed by Z. A. Varga; Mr J. F. Thompson; R. N. Baird; P. M. Lamont

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
95 KB
Volume
81
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The future of vascular surgery
The future of vascular surgery
✍ Mr. J. D. Beard; P. A. Gaines πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 268 KB

Peripheral vascular disease is a growing problem in the developed world because of smoking and an increasingly elderly population. The rise in workload detailed by the Vascular Registry in Southern Sweden' shows that the number of operations per lo6 inhabitants per year increased from fewer than 300

The future of vascular surgery
The future of vascular surgery
✍ N. J. M. London; P. R. F. Bell; R. J. Cuschieri; J. Y. MacKinlay; R. N. Baird; P πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 279 KB
The role of fibrin adhesive in vascular
The role of fibrin adhesive in vascular surgery
✍ M. G. Ikossi-O'Connor; J. L. Ambrus; Uma Rao πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 202 KB

Fibrin Seal (FS) (a natural adhesive material composed of fibrinogen, cold insoluble globulin, factor XIII, platelet growth factor, antiplasmin thrombin, and calcium chloride) was utilized in the construction of vascular anastomosis of the femoral artery of mongrel dogs. A significant decrease in th

Heparin/dihydroergotamine for venous thr
Heparin/dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery
✍ Dr. M. R. Lassen; L. C. Borris; H. M. Christiansen; F. MΓΈller-Larsen; V. E. Knud πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 495 KB πŸ‘ 2 views

Abstract In a prospective, double-blind controlled study we have compared the prophylactic efficacy against deep vein thrombosis of low-dose heparin + dihydroergotamine (A), low molecular weight heparin + dihydro-ergotamine (B) and placebo (C). A total of three hundred and fifty-six patients undergo